Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study. | Zendy

G Fornaro | Zendy; P Rossi | Zendy; P G Mantica | Zendy; M. Caccia | Zendy; D Aralda | Zendy; M Lavezzari | Zendy; F. Pamparana | Zendy; G. Milanesi | Zendy

Open Access

Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study.

Author(s) -

G Fornaro,

P Rossi,

P G Mantica,

M. Caccia,

D Aralda,

M Lavezzari,

F. Pamparana,

G. Milanesi

Publication year - 1993

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/01.cir.87.1.162

Subject(s) - medicine , placebo , myocardial infarction , stroke (engine) , clinical endpoint , cardiology , atrial fibrillation , pulmonary embolism , adverse effect , randomized controlled trial , anesthesia , mechanical engineering , alternative medicine , pathology , engineering

The purpose of this randomized, double-blind study was to evaluate the efficacy of indobufen, a reversible inhibitor of platelet cyclooxygenase, in the prevention of embolic events of cardiac origin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research